Genomic analyses have redefined the molecular subgrouping of pediatric acute lymphoblastic leukemia (ALL). Molecular subgroups guide risk-stratification and targeted therapies, but outcomes of recently identified subtypes are often unclear, owing to limited cases with comprehensive profiling and cross-protocol studies. We developed a machine learning tool (ALLIUM) for the molecular subclassification of ALL in retrospective cohorts as well as for up-front diagnostics. ALLIUM uses DNA methylation and gene expression data from 1131 Nordic ALL patients to predict 17 ALL subtypes with high accuracy. ALLIUM was used to revise and verify the molecular subtype of 281 B-cell precursor ALL (BCP-ALL) cases with previously undefined molecular phenotype...
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer in the Nordic countries. Rece...
Gene expression analyses were performed on 121 consecutive childhood leukemias (87 B-lineage acute l...
Although children with acute lymphoblastic leukemia (ALL) generally have a good outcome, some patien...
Background: We present a method that utilizes DNA methylation profiling for prediction of the cytoge...
Background: We present a method that utilizes DNA methylation profiling for prediction of the cytoge...
To access publisher's full text version of this article, please click on the hyperlink in Additional...
To access publisher full text version of this article. Please click on the hyperlink in Additional L...
Background: Genetic subtypes of acute lymphoblastic leukaemia (ALL) are used to determine risk and t...
Background Genetic subtypes of acute lymphoblastic leukaemia (ALL) are used to determine risk and tr...
AbstractTreatment of pediatric acute lymphoblastic leukemia (ALL) is based on the concept of tailori...
Abstract RNA sequencing provides a snapshot of the functional consequences of genomic lesions that ...
Leukemia is the most common malignant disease in children patients. In our laboratory (CLIP) a novel...
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer in the Nordic countries. Stru...
Acute lymphoblastic leukemia (ALL) is the most frequent malignant disease in the pediatric populatio...
Background. Despite increased knowledge about genetic aberrations in pediatric T-cell acute lymphobl...
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer in the Nordic countries. Rece...
Gene expression analyses were performed on 121 consecutive childhood leukemias (87 B-lineage acute l...
Although children with acute lymphoblastic leukemia (ALL) generally have a good outcome, some patien...
Background: We present a method that utilizes DNA methylation profiling for prediction of the cytoge...
Background: We present a method that utilizes DNA methylation profiling for prediction of the cytoge...
To access publisher's full text version of this article, please click on the hyperlink in Additional...
To access publisher full text version of this article. Please click on the hyperlink in Additional L...
Background: Genetic subtypes of acute lymphoblastic leukaemia (ALL) are used to determine risk and t...
Background Genetic subtypes of acute lymphoblastic leukaemia (ALL) are used to determine risk and tr...
AbstractTreatment of pediatric acute lymphoblastic leukemia (ALL) is based on the concept of tailori...
Abstract RNA sequencing provides a snapshot of the functional consequences of genomic lesions that ...
Leukemia is the most common malignant disease in children patients. In our laboratory (CLIP) a novel...
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer in the Nordic countries. Stru...
Acute lymphoblastic leukemia (ALL) is the most frequent malignant disease in the pediatric populatio...
Background. Despite increased knowledge about genetic aberrations in pediatric T-cell acute lymphobl...
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer in the Nordic countries. Rece...
Gene expression analyses were performed on 121 consecutive childhood leukemias (87 B-lineage acute l...
Although children with acute lymphoblastic leukemia (ALL) generally have a good outcome, some patien...